Corona Remedies

Corona Remedies makes bumper D-St debut; lists at 38% premium on bourses

Corona Remedies shares opened at ₹1,470 on the NSE, a premium of ₹408 or 38 per cent from the issue price of ₹1,062

IPO Calendar: Busy week; ICICI Pru AMC, Corona Remedies debut in focus

Upcoming IPO Calendar: Corona Remedies and Wakefit Innovations are set to debut on Friday, December 15, followed by Nephrocare Health and Park Medi World, both scheduled to list on Sunday, December 17

Corona Remedies IPO to list on Dec 15; here's what GMP hints for D-St debut

Corona Remedies IPO received an overwhelming investor interest, achieving an overall oversubscription of 137 times, driven largely by strong participation from QIBs

Last day! Corona Remedies IPO closes today; subscription rises 50x, GMP 25%

Corona Remedies IPO received bids for 229.5 million shares against 4.57 million shares on offer as of 02:00 PM on December 10

Corona Remedies IPO off to a lukewarm start; GMP holds steady at 27%

Corona Remedies IPO: Check price band, lot size GMP, subscription status, reviews, and other key details here

IPO Calendar: D-Street braces for 9 new issues; Meesho, Aequs listings

IPO Calendar: Nephrocare, Park Medi World, Wakefit Innovations, and Corona Remedies, are set to open for subscription, aiming to raise a combined ₹3,735 crore

Corona Remedies IPO opens Dec 8: Bid or skip? Here's what experts suggest

Corona Remedies IPO Date: The unlisted shares of Corona Remedies were trading at ₹1,427, commanding a grey market premium of ₹365 or 34.4 per cent on Friday

Corona Remedies IPO opens Dec 8: GMP at 31%; 5 key risks you should know

Corona Remedies IPO will be offered at a price band of ₹1,008 to ₹1,062 per share, with a lot size of 14 shares

Corona Remedies IPO price band at ₹1,008-1,062; check dates, GMP, objective

Corona Remedies aims to raise ₹655.37 crore through an offer for sale of 6.2 million equity shares

CORONA Remedies acquires 7 pharma brands from Bayer India, plans expansion

CORONA Remedies deepens footprint in women's healthcare and cardiology with Bayer India portfolio acquisition, entering anti-platelet and hormone therapy segments

Covid-19 cases cross 250 mark in India: Should you worry about JN.1 variant?

Doctors explain what the Covid JN.1 variant is, its symptoms, vaccine protection, testing options, and what precautions Indians should take amid rising cases in Asia

AstraZeneca's anti-Covid drug cuts disease risk in vulnerable patients

The long-acting antibody therapy called sipavibart showed a "statistically significant reduction" in symptomatic Covid-19 cases among immunocompromised patients

Novavax signs Covid-19 license deal with Sanofi, secures business viability

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

AstraZeneca withdraws its Covid-19 vaccine, cites 'surplus availability'

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts

Former Rajasthan CM Ashok Gehlot tests positive for Covid-19, swine flu

Former Rajasthan chief minister Ashok Gehlot on Friday said he has tested positive for COVID-19 and swine flu. In a post on X, the Congress leader advised people to take care of their health in the changing season. "Due to fever for the last few days, today I got myself tested on the advice of doctors which confirmed (that I have) Covid and swine flu. Because of this, I will not be able to meet (anyone) for the next seven days," Gehlot said. "In this changing season, everyone should also take care of their health," he said.

India registers 133 fresh Covid-19 cases, active caseload at 1,389

India saw a single-day rise of 133 Covid cases, while the number of active cases stood at 1,389, the Union health ministry said on Wednesday. Two deaths -- one each from Gujarat and Maharashtra -- have been reported in 24 hours, according to the ministry's data updated at 8 am. The number of daily cases had dropped to double-digits till December 5, but cases had begun to increase after the emergence of a new variant and cold weather conditions. After December 5, a maximum of a single-day rise of 841 new cases was reported on December 31, 2023, which is 0.2 per cent of the peak cases reported in May 2021, official sources said. A majority (around 92 per cent) of the total active cases are under home isolation, they said. "The currently available data suggests that the JN.1 variant is neither leading to an exponential rise in the new cases nor a surge in the hospitalisation and mortality," the official source stated. India has witnessed three waves of COVID-19 in the past with the

India registers 305 new Covid-19 cases, active cases decline to 2,439

India saw a single day rise of 305 new cases of COVID-19, while the number of active cases of the infection has declined to 2,439, the health ministry said on Thursday. Three deaths -- one each from Maharashtra, Karnataka and Gujarat -- have been reported in a span of last 24 hours, according to the ministry's data updated at 8 am. The number of daily cases had dropped to double-digits till December 5, but cases began to increase after emergence of a new variant and cold weather conditions. After December 5, a maximum of a single-day rise of 841 new cases were reported on December 31, which is 0.2 per cent of the peak cases reported in May 2021, official sources said. Of the total active cases, around 92 per cent are recovering under home isolation. "The currently available data suggests that the JN.1 sub-variant is neither leading to an exponential rise in the new cases nor a surge in the hospitalisation and mortality," the official source stated. India has witnessed three waves

World yet not fully prepared for future pandemics: Gates Foundation prez

Praising India and other countries for contributing to a global pandemic fund, a top official of the Bill and Melinda Gates Foundation on Tuesday said the world is yet not fully prepared to deal with any future pandemic and a lot more work needs to be done. Speaking to PTI on the sidelines of the World Economic Forum Annual Meeting, where 'Disease X' is one of the key areas of discussions, Dr Christopher J Elias said we have learnt our lessons after Covid-19 but further efforts and discussions are needed, including on financing requirements. "A really important discussion had started nearly eight years ago after the Ebola outbreak and that discussion cake into very clear focus after Covid-19 that the world needs to be better prepared," he said. "The world needs to be ready for infections and diseases that we know such as influenza but also diseases that we don't know and may be new such as Disease X. But I don't think we are fully prepared yet," he added. Elias noted that there hav

Covid-19 JN.1: UP joins list of 16 states, UTs; total cases cross 1,000

The number of cases of COVID-19 sub-variant JN.1 has crossed 1,000 mark with Uttar Pradesh becoming the latest state to join the list of 16 states and UTs which have detected its presence, according to INSACOG. The data compiled by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) showed Karnataka has reported the highest number of cases at 214, followed by Maharashtra (170), Kerala (154), Andhra Pradesh (189), Gujarat (76) and Goa (66). Telangana and Rajasthan have recorded 32 JN.1 cases each, Chhattisgarh has recorded 25, Tamil Nadu 22, Delhi 16, Uttar Pradesh 6, Haryana five, Odisha three, West Bengal two and Uttarakhand one, according to the data. A total of 1,013 cases of JN.1 have been detected till now across the 16 states and UTs. The Centre has asked the states and Union territories to maintain a constant vigil amid an uptick in the number of Covid cases and the detection of the JN.1 sub-variant in the country. The states have been urged to ensure effective compliance o

819 cases of Covid-19 sub-variant JN.1 reported from 12 states: Govt

A total of 819 cases of COVID-19 sub-variant JN.1 were reported from 12 states till Monday, official sources said. They said 250 cases were reported from Maharashtra, 199 from Karnataka, 148 from Kerala, 49 from Goa, 36 from Gujarat, 30 each from Andhra Pradesh and Rajasthan, 26 each from Tamil Nadu and Telangana, 21 from Delhi, three from Odisha and one from Haryana. Even though the number of JN.1 cases is rising, there is no cause of immediate concern as the majority of those infected are opting for home-based treatment, indicating a mild illness, officials said. The Centre has asked the states and Union territories to maintain a constant vigil amid an uptick in the number of Covid cases and the detection of the JN.1 sub-variant of the virus in the country. The states have been urged to ensure effective compliance of the detailed operational guidelines for the revised Covid surveillance strategy shared with them by the Union Ministry of Health and Family Welfare. The states have